Skip to content
Sulfisoxazole
Eryzole, Gantrisin, Ilosone Sulfa, Pediazole, Sosol, Soxazole, Sulfalar, Sulsoxin (sulfisoxazole) is a small molecule pharmaceutical. Sulfisoxazole was first approved as Pediazole on 1982-01-01. It is used to treat bacterial infections, chlamydia infections, mycoses, nocardia infections, and otitis media amongst others in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
respiratory tract diseasesD012140
otorhinolaryngologic diseasesD010038
urogenital diseasesD000091642
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Erythromycin estolate
+
Sulfisoxazole acetyl
Tradename
Company
Number
Date
Products
ILOSONE SULFAEli LillyN-050599 DISCN1989-09-29
1 products
Hide discontinued
Erythromycin ethylsuccinate
+
Sulfisoxazole acetyl
Tradename
Company
Number
Date
Products
PEDIAZOLERoss LaboratoriesN-050529 DISCN1982-01-01
1 products
Hide discontinued
Phenazopyridine hydrochloride
+
Sulfisoxazole
Tradename
Company
Number
Date
Products
AZO GANTRISINRocheN-019358 DISCN1990-08-31
1 products, RLD
Hide discontinued
Sulfisoxazole
Tradename
Company
Number
Date
Products
GANTRISINRocheN-006525 DISCN1982-01-01
1 products
Hide discontinued
Sulfisoxazole acetyl
Tradename
Company
Number
Date
Products
GANTRISINRocheN-009182 DISCN1982-01-01
1 products
GANTRISIN PEDIATRICRocheN-009182 DISCN1982-01-01
1 products
LIPO GANTRISINRocheN-009182 DISCN1982-01-01
1 products
Hide discontinued
Sulfisoxazole diolamine
Tradename
Company
Number
Date
Products
GANTRISINRocheN-006917 DISCN1982-01-01
1 products
GANTRISINRocheN-007757 DISCN1982-01-01
1 products
GANTRISINRocheN-008414 DISCN1982-01-01
1 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
erythromycin ethylsuccinate and sulfisoxazole acetylANDA2011-01-17
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
bacterial infectionsD001424A49
chlamydia infectionsEFO_0007205D002690A74.9
mycosesD009181B35-B49
nocardia infectionsEFO_0007397D009617A43
otitis mediaEFO_0004992D010033H66.9
protozoan infectionsD011528B50-B64
respiratory tract fistulaD016156
urinary tract infectionsEFO_0003103D014552N39.0
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
J01: Antibacterials for systemic use
J01E: Sulfonamides and trimethoprim antibacterials for systemic use
J01EB: Short-acting sulfonamides
J01EB05: Sulfafurazole
S: Sensory organ drugs
S01: Ophthalmologicals
S01A: Antiinfective ophthalmologics
S01AB: Sulfonamides, ophthalmologic antiinfectives
S01AB02: Sulfafurazole
HCPCS
No data
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameSULFISOXAZOLE
INNsulfafurazole
Description
Sulfisoxazole is a sulfonamide antibacterial with an oxazole substituent. It has antibiotic activity against a wide range of gram-negative and gram-positive organisms. It has a role as an antibacterial drug and a drug allergen. It is a member of isoxazoles, a sulfonamide and a sulfonamide antibiotic. It is functionally related to a sulfanilamide.
Classification
Small molecule
Drug class
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C
Identifiers
PDB
CAS-ID127-69-5
RxCUI10207
ChEMBL IDCHEMBL453
ChEBI ID102484
PubChem CID5344
DrugBankDB00263
UNII ID740T4C525W (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 2,339 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
7 adverse events reported
View more details